loader
Please Wait
Applying Filters...

Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Mln2238, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Mln2238

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    DIGITAL CONTENT

    PharmaCompass

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    2D Structure
    1. Also known as: 1072833-77-2, Mln2238, Mln-2238, Mln 2238, Ixazomib [inn], (r)-(1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)boronic acid
    Molecular Formula
    C14H19BCl2N2O4
    Molecular Weight
    361.0  g/mol
    InChI Key
    MXAYKZJJDUDWDS-LBPRGKRZSA-N
    FDA UNII
    71050168A2
    Ixazomib is an active metabolite of MLN9708, a second generation, boron containing peptide proteasome inhibitor (PI) with potential antineoplastic activity. Ixazomib binds to and inhibits the 20S catalytic core of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins; disruption of various cell signaling pathways may follow, resulting in the induction of apoptosis. Compared to first generation PIs, second generation PIs may have an improved pharmacokinetic profile with increased potency and less toxicity. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquinated.
    Ixazomib is a Proteasome Inhibitor. The mechanism of action of ixazomib is as a Proteasome Inhibitor.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    [(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]boronic acid
    2.1.2 InChI
    InChI=1S/C14H19BCl2N2O4/c1-8(2)5-12(15(22)23)19-13(20)7-18-14(21)10-6-9(16)3-4-11(10)17/h3-4,6,8,12,22-23H,5,7H2,1-2H3,(H,18,21)(H,19,20)/t12-/m0/s1
    2.1.3 InChI Key
    MXAYKZJJDUDWDS-LBPRGKRZSA-N
    2.1.4 Canonical SMILES
    B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O
    2.1.5 Isomeric SMILES
    B([C@H](CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O
    2.2 Other Identifiers
    2.2.1 UNII
    71050168A2
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Mln 9708

    2. Mln-9708

    3. Mln9708

    4. Ninlaro

    2.3.2 Depositor-Supplied Synonyms

    1. 1072833-77-2

    2. Mln2238

    3. Mln-2238

    4. Mln 2238

    5. Ixazomib [inn]

    6. (r)-(1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)boronic Acid

    7. (r)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutylboronic Acid

    8. Ixazomib (mln2238)

    9. Mln-9708 Free Base

    10. Chembl2141296

    11. Ixazomib (usan)

    12. Ixazomib [usan]

    13. [(1r)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]boronic Acid

    14. [(1r)-1-{2-[(2,5-dichlorophenyl)formamido]acetamido}-3-methylbutyl]boronic Acid

    15. Boronic Acid, B-((1r)-1-((2-((2,5-dichlorobenzoyl)amino)acetyl)amino)-3-methylbutyl)-

    16. 71050168a2

    17. Ixazomib [usan:inn]

    18. Ixozamib

    19. Ixazomib Impurity

    20. Unii-71050168a2

    21. Ixazomib(mln2238)

    22. Mln2238(ixazomib)

    23. Ixazomib [mi]

    24. Ixazomib [who-dd]

    25. Ixazomib (mln-2238)

    26. Gtpl8450

    27. Schembl3742758

    28. Chebi:90942

    29. Ex-a547

    30. Dtxsid701025662

    31. Amy19380

    32. Bcp02410

    33. Bcp24078

    34. Bdbm50398609

    35. Mfcd18251438

    36. Nsc766907

    37. S2180

    38. Akos015995120

    39. Zinc169946773

    40. Bcp9000953

    41. Ccg-264938

    42. Cs-1657

    43. Db09570

    44. Nsc-766907

    45. 1072833-77-2 (free)

    46. Ncgc00249611-01

    47. Ncgc00249611-03

    48. Ncgc00249611-04

    49. Ac-28456

    50. As-55976

    51. Hy-10453

    52. Sw219743-1

    53. J3.602.191h

    54. A25328

    55. D10130

    56. J-001749

    57. Brd-k78659596-001-01-3

    58. Q20948663

    59. N-[(1r)-1-borono-3-methylbutyl]-n(2)-(2,5-dichlorobenzoyl)glycinamide

    60. ((1r)-1-((2,5-dichlorobenzamido)acetamido)-3-methylbutyl)boronic Acid

    61. (r)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutylboronic Acid;ixazomib

    62. [(1r)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methyl-butyl]boronic Acid

    2.4 Create Date
    2009-03-16
    3 Chemical and Physical Properties
    Molecular Weight 361.0 g/mol
    Molecular Formula C14H19BCl2N2O4
    Hydrogen Bond Donor Count4
    Hydrogen Bond Acceptor Count4
    Rotatable Bond Count7
    Exact Mass360.0814926 g/mol
    Monoisotopic Mass360.0814926 g/mol
    Topological Polar Surface Area98.7 Ų
    Heavy Atom Count23
    Formal Charge0
    Complexity412
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

    FDA Label

    Treatment of lymphoid malignancies (excluding multiple myeloma)

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    In vitro studies have shown ixazomib to induce apoptosis in multiple myeloma cells sensitive or resistant to other conventional therapies. In mouse xenograft models, ixazomib induced tumor growth inhibition.

    5.2 MeSH Pharmacological Classification

    Antineoplastic Agents

    Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

    Protease Inhibitors

    Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). (See all compounds classified as Protease Inhibitors.)

    5.3 FDA Pharmacological Classification
    5.3.1 Active Moiety
    IXAZOMIB
    5.3.2 FDA UNII
    71050168A2
    5.3.3 Pharmacological Classes
    Proteasome Inhibitors [MoA]; Proteasome Inhibitor [EPC]
    5.4 ATC Code

    L - Antineoplastic and immunomodulating agents

    L01 - Antineoplastic agents

    L01X - Other antineoplastic agents

    L01XG - Proteasome inhibitors

    L01XG03 - Ixazomib

    5.5 Absorption, Distribution and Excretion

    Absorption

    After oral administration, the time to reach maximum concentration in plasma was 1 hour. The mean absolute oral bioavailability is 58%.

    Route of Elimination

    62% in urine and 22% in feces.

    Volume of Distribution

    The steady-state volume of distribution is 543 L.

    5.6 Metabolism/Metabolites

    Metabolism of ixazomib is expected to be by CYP and non-CYP pathways, with no predominant CYP isozyme contribution. At higher than clinical concentrations, ixazomib was metabolized by multiple CYP isoforms with estimated relative contributions of 3A4 (42%), 1A2 (26%), 2B6 (16%), 2C8 (6%), 2D6 (5%), 2C19 (5%) and 2C9 (<1%).

    5.7 Biological Half-Life

    Terminal half-life is 9.5 days.

    5.8 Mechanism of Action

    Ixazomib is an N-capped dipeptidyl leucine boronic acid which reversibly inhibits the CT-L proteolytic (5) site of the 20S proteasome. At higher concentrations, ixazomib also seems to inhibit the proteolytic 1 and 2 subunits and to induce accumulation of ubiquitinated proteins.

    Post Enquiry
    POST ENQUIRY